Grifols (NASDAQ:GRFS) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Grifols (NASDAQ:GRFS) from a buy rating to a hold rating in a research report released on Sunday.

A number of other research firms have also weighed in on GRFS. Zacks Research upgraded shares of Grifols from a “strong sell” rating to a “hold” rating in a research note on Friday, February 6th. Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a research report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. cut their price target on Grifols from $10.30 to $10.00 and set a “neutral” rating for the company in a report on Monday, December 8th. Four research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Grifols currently has an average rating of “Hold” and a consensus target price of $10.00.

Grifols Trading Down 6.4%

Shares of NASDAQ:GRFS opened at $8.20 on Friday. The company has a current ratio of 2.51, a quick ratio of 0.88 and a debt-to-equity ratio of 1.20. The company has a 50-day moving average price of $9.16 and a two-hundred day moving average price of $9.26. Grifols has a twelve month low of $6.19 and a twelve month high of $11.14.

Institutional Trading of Grifols

Hedge funds and other institutional investors have recently bought and sold shares of the company. Brandes Investment Partners LP lifted its stake in Grifols by 6.3% in the 4th quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock worth $289,422,000 after purchasing an additional 1,838,727 shares in the last quarter. Capital World Investors increased its holdings in shares of Grifols by 5.9% in the third quarter. Capital World Investors now owns 22,926,140 shares of the biotechnology company’s stock worth $228,344,000 after purchasing an additional 1,273,391 shares during the period. Permian Investment Partners LP increased its holdings in shares of Grifols by 4.2% in the fourth quarter. Permian Investment Partners LP now owns 18,190,262 shares of the biotechnology company’s stock worth $170,079,000 after purchasing an additional 737,941 shares during the period. Millennium Management LLC raised its position in shares of Grifols by 2.7% in the fourth quarter. Millennium Management LLC now owns 7,122,155 shares of the biotechnology company’s stock worth $66,592,000 after buying an additional 184,874 shares in the last quarter. Finally, Bank of Montreal Can raised its position in shares of Grifols by 45.8% in the fourth quarter. Bank of Montreal Can now owns 4,394,750 shares of the biotechnology company’s stock worth $41,091,000 after buying an additional 1,381,027 shares in the last quarter.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.